Immutep (NASDAQ: IMMP) jumps 15% as efti review points to manufacturing differences

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has given investors the first tangible technical explanation that could help reconcile the unexpected failure of its Phase 3 TACTI-004 study with earlier positive results for eftilagimod alfa, identifying subtle analytical differences between material manufactured at 200-litre and 2,000-litre scale. The Australian biotechnology company has now contracted a new 200-litre manufacturing run and intends to focus future registration-directed development on selected head and neck cancer and soft tissue sarcoma settings.

Immutep stressed that its root-cause analysis remains ongoing, so the manufacturing finding should not be treated as proof that scale-up alone caused TACTI-004 to fail. The company said structural differences, including a subtle change in N-glycan structure, are considered potentially relevant because TACTI-004 produced a markedly different immune-activation profile from earlier trials, while clinical protocol, randomisation, safety and general trial-execution issues have not so far explained the unexpected result.

Why is the 200-litre versus 2,000-litre finding so important?

Drug manufacturing is not merely a logistics exercise, particularly for complex biological products. Scaling a biologic from a smaller bioreactor to commercial-scale production can change process conditions in ways that potentially affect molecular attributes even when batches continue to satisfy predefined release specifications.

That context is especially striking because Immutep announced in 2022 that it had successfully completed its first 2,000-litre efti manufacturing run after scaling up from 200 litres. The company considered the larger-scale process important preparation for late-stage trials and potential commercial production, and the material met the predefined release criteria used at the time.

TACTI-004 was subsequently conducted exclusively using efti manufactured at the 2,000-litre scale. In contrast, Immutep said ten GMP batches made at 200 litres had previously been used in successful Phase 1 and Phase 2 studies including TACTI-mel, TACTI-002 and INSIGHT-003.

That does not establish causation, but it provides a scientifically plausible variable that was materially different between the unsuccessful Phase 3 study and several earlier studies. For a biotechnology company whose lead programme suffered a late-stage setback, even identifying a credible hypothesis is strategically valuable because it can influence whether further development is rational.

Does this mean TACTI-004 failed because of manufacturing?

Not yet. That would go beyond what Immutep has established. The company has described the analytical differences as potentially relevant and said the root-cause investigation is continuing.

The distinction matters because retrospective explanations after a failed Phase 3 study face a high evidentiary bar. Investors should want to see whether the identified molecular differences translate into measurable differences in biological potency, pharmacodynamics or clinical activity, rather than simply correlating with two manufacturing scales.

Immutep has nevertheless narrowed the field of possible explanations. Management said currently available analysis does not indicate that the outcome can be explained by an inadequate protocol, substantial treatment-arm imbalance, safety issue, invalid randomisation pattern or general trial conduct.

The new 200-litre manufacturing run therefore functions as both a supply decision and an experiment. If future analytical and clinical work reproduces the characteristics seen in earlier successful material, confidence in the manufacturing hypothesis could strengthen. If it does not, the company will need another explanation for why the programme’s Phase 3 behaviour diverged so sharply from previous evidence.

Why is Immutep narrowing efti development to two cancer settings?

Immutep currently intends to focus registration-directed efti development on head and neck squamous cell carcinoma patients with negative PD-L1 expression, defined as Combined Positive Score below 1, and on neoadjuvant soft tissue sarcoma. The company believes those settings offer a combination of clinical evidence, biological rationale, regulatory support and unmet need.

The head and neck programme already has U.S. Food and Drug Administration Fast Track designation, while efti received Orphan Drug Designation for soft tissue sarcoma in April 2026. Immutep said preparations for new studies have begun, with trial starts targeted for the second half of calendar 2027, subject to final protocol design, regulatory interactions, manufacturing, partnering and available resources.

That represents a more conservative strategy than immediately attempting another broad Phase 3 programme. Instead of trying to prove efti across the largest possible population, Immutep is concentrating capital on settings where previous clinical evidence may provide the clearest chance of demonstrating a reproducible effect.

Can Immutep finance the reset without immediately returning to shareholders?

Immutep ended June 2026 with A$68.87 million in cash, cash equivalents and term deposits. Following cost-reduction measures implemented after the TACTI-004 disappointment, the company said its existing resources were expected to provide a runway into the first half of calendar 2028.

That runway is meaningful because the next efti trials are not expected to begin until the second half of 2027. On the current timetable, Immutep has time to complete manufacturing work, regulatory discussions and study design before committing fully to another expensive registration-directed programme.

However, the cash runway should not be interpreted as proof that all future pivotal development can be financed internally. Large oncology trials can consume substantial capital, and management explicitly listed partnering and resources among the factors that will determine the next trial starts. The eventual scale of the programme could therefore reopen financing questions well before commercialisation.

Why did Immutep shares rally so sharply?

Immutep’s Nasdaq-listed American depositary shares closed at $0.373 on September 11, up 14.77%, while volume rose to approximately 2.93 million shares from about 151,000 a day earlier. The Australian-listed shares also reacted strongly to the strategy update, indicating that investors viewed the manufacturing finding as meaningfully better than a scenario in which TACTI-004 had simply invalidated efti’s mechanism.

The rally should nevertheless be interpreted carefully. The market is repricing probability, not declaring efti rescued. Immutep still has to complete the root-cause investigation, reproduce suitable drug material, agree future trial designs with regulators and ultimately generate new clinical data.

The most important change is that the TACTI-004 failure now has a technically testable hypothesis attached to it. That gives Immutep a pathway forward and may preserve more value in efti than investors feared after the Phase 3 discontinuation. The next challenge is proving that the explanation survives prospective testing rather than remaining a compelling retrospective theory.